Key result
Review highlights clinical successes and persistent challenges in understanding, preventing, and treating chronic Chagas cardiomyopathy.
Why the study?
Despite scientific progress, many challenges remain in understanding, preventing, and treating chronic Chagas cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Chronic Chagas cardiomyopathy (CCC) is the most serious complication of Chagas disease. More than a century after the astute clinician-scientist Carlos Chagas published the etiologic, pathological, clinical, and epidemiological characteristics of the disease that now bears his name [1], much scientific progress has been made. Nevertheless, many challenges still remain. In this article, we provide a brief perspective on the clinical and public health successes as well as a summary of the biomedical research portfolio supported by the National Heart, Lung, and Blood Institute (NHLBI). Finally, we explore the compelling research questions and critical challenges for better understanding CCC and tackling its prevention and treatment.
No takes yet. Share an insight, caveat, or question.
Mensah et al. (2015) conducted a review in Chronic Chagas cardiomyopathy. This article provides a perspective on clinical successes, NHLBI-supported research, and critical challenges for better understanding, preventing, and treating chronic Chagas cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: